Things to Consider when Starting Patients on Warfarin
|
|
- Lewis Chase
- 2 years ago
- Views:
Transcription
1 Things to Consider when Starting Patients on Warfarin 1. Ensure that patient doesn t have any of these absolute contraindication for warfarin 1 Pregnancy, except in women with mechanical heart valves Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system (CNS) or eye, or traumatic surgery resulting in large open surfaces Bleeding tendencies associated with certain conditions Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with potential high levels of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or any component of the product Major regional or lumbar block anesthesia Malignant hypertension 2. Weigh risk of clotting with risk of bleeding In a-fib patients, calculate the patient s stroke risk using CHADS 2 or CHA 2 DS 2 -VASc scores and bleeding risk using the HAS-BLED score. In VTE patients, calculate the patient s bleeding risk using the RIETE bleeding risk score. 3. Consider other patient factors that could impact warfarin safety Possible drug interactions (drug interaction table) Ability of patient/family to comply with monitoring and dose changes and comprehend warfarin education Alcohol abuse, dementia, depression, unstable diet, co-morbidities Discuss treatment options with cardiologist if patient is also on dual antiplatelet medications 4. Select appropriate target INR range Selecting appropriate target range 5. Select appropriate treatment duration Selecting appropriate duration 6. Select appropriate starting dose Select starting dose based on factors affecting bleeding risk and warfarin sensitivity such as age, co-morbidities, and interacting drugs. 1 Coumadin package insert: Copyright 2014, MAQI 2 For questions or permissions, please Version 1.2, reviewed/updated on 2/1/15 Page 17
2 Warfarin Target INR Range and Length of Treatment Table 1. Recommendations for Target INR Range and Duration of Treatment Adapted from American College of Chest Physicians Guidelines 1 Indication DVT and PE 2 PE or DVT of leg provoked by surgery or transient/reversible risk factor PE or DVT of leg unprovoked by surgery or transient/reversible risk factor PE or DVT of leg in patients with active cancer Target INR Range Recommended Duration months 1B 2-3 At least 3 months, then evaluate for risk-benefit of extended therapy (see flowchart below) 2-3 Extended (>3 months) Suggest use of LMWH over 2B warfarin in DVT of leg Non valvular atrial fibrillation and/or flutter 3 Low risk (CHADS2=0) N/A ASA mg or no therapy 2B Intermediate risk (CHADS2=1) 1B Grade of Recommendation 1B (2B if high-risk for bleed) 2-3 Long-term 1B for oral anticoagulation 2B for dabigatran over warfarin* High risk (CHADS2 > 2) 2-3 Long-term 1A for oral anticoagulation 2B for dabigatran over warfarin* AF with mitral stenosis 2-3 Long-term 1B AF with stable CAD 2-3 Long-term 2C Cardioversion 2-3 At least 3 weeks prior 1B Valvular Disease 3 Bioprosthetic in mitral position At least 4 weeks after 2-3 First 3 months after insertion. After 3 months and if patient is in normal sinus rhythm, aspirin therapy is suggested. Mechanical aortic valve 2-3 Indefinite 1B over higher targets 2C over lower targets 2C Add anti-platelet such as low-dose aspirin, if patient at low risk for bleeding (1B) Copyright 2014, MAQI 2 For questions or permissions, please Version 1.2, reviewed/updated on 2/1/15 Page 18
3 Mechanical mitral valve Indefinite 2C over lower targets Mechanical valves in both aortic and mitral positions Add anti-platelet such as low-dose aspirin, if patient at low risk for bleeding (1B) Indefinite 2C over lower targets Post-op VTE prophylaxis 4** Total hip replacement At least 10 to 14 days Add anti-platelet such as low-dose aspirin, if patient at low risk for bleeding (1B) 1B Suggestion to extend up to 35 days Total knee replacement At least 10 to 14 days Suggestion to extend up to 35 days Hip fracture surgery At least 10 to 14 days 2B 1B 2B 1B Suggestion to extend up to 35 days *Target specific oral anticoagulants, including dabigatran, rivaroxaban, apixaban, and edoxaban have been given FDA approval for stroke prevention in non-valvular atrial fibrillation patients and represent viable alternatives to warfarin. At the writing of the 9 th ed of the CHEST guidelines, only dabigatran had FDA approval. The guidelines suggest dabigatran 150mg BID over warfarin (Grade 2B) except in patients with mitral stenosis or stable CAD. **LMWH is recommended over warfarin for post-op VTE prophylaxis (Grade 2C) 4 1 Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians. 2 Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. doi: /chest Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. doi: /chest Prevention of VTE in Orthopedic Surgery PatientsAntithrombotic Therapy and Prevention of Thrombosis,9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141(2)(Suppl):e278S e325s 2B Copyright 2014, MAQI 2 For questions or permissions, please Version 1.2, reviewed/updated on 2/1/15 Page 19
4 Length of treatment recommendations for idiopathic (unprovoked) VTE 1 Occurrence of idiopathic VTE First Second PE or Proximal DVT of Leg Isolated distal DVT of leg PE or DVT of leg High Bleeding Risk Low- Moderate Bleeding Risk Low, Moderate, or High Bleeding Risk Low Moderate Bleeding Risk High Bleeding Risk 3 months of therapy (1B rec) Extended (> 3 months) of therapy (2B rec) 3 months of therapy (2B/1B rec) Extended(>3 months) of therapy (1B/2B rec) 3 months of therapy (2B rec) 1 Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. doi: /chest Return to Things to Consider when Starting Patients on Warfarin Copyright 2014, MAQI 2 For questions or permissions, please Version 1.2, reviewed/updated on 2/1/15 Page 20
5 Selection of Warfarin Starting Dose Patient population Most patients Follow 5mg initiation nomogram after first two 5mg doses. Patients with acute VTE being treated in the outpatient setting and are low to moderate risk for bleeding 1 Follow 10 mg initiation nomogram after first two 10mg doses. High bleeding risk patients (ex. elderly, malnourished, CHF, hepatic dysfunction, interacting drugs such as amiodarone) Initial dose 5mg 10mg Loading dose of 10mg daily for 2 days and then dosing based on INR measurements is a 2C recommendation in the latest ACCP guidelines for patients sufficiently health to be treated as outpatients where rapid attainment of therapeutic INR is required and considered safe 3 Consider 2.5mg* *MAQI 2 expert consensus Selecting the initial starting dose involves assessing the patient s bleeding risk, need for rapid anticoagulation, and treatment environment. Two small randomized trials have compared 5mg and 10mg starting doses. Study Patient population Methods Results Kovacs 1 Crowther 2 Acute VTE, outpatient setting, concurrent LMWH treatment, 25% had CA, mean age 55 Patients excluded: baseline INR>1.4, thrombocytopenia, <18 years old, required hospitalization, high-risk for bleeding Acute VTE, inpatient setting, most had concurrent heparin treatment, 1/3 had CA, mean age patients randomized to receive either 5mg or 10mg initial dosing. 53 patients randomized to receive either 5mg or 10mg initial dosing. An INR should be obtained within 3-5 days after starting warfarin to assess initial response 10mg superior to 5mg Patients with 10mg initial dosing reached first in-range INRs 1.4 days sooner and had similar rates of bleeding AEs and supratherapeutic INRs as patients started on 5mg. 5mg just as good and possibly safer 5mg initial dosing resulted in therapeutic INRs as quickly as 10mg dosing with a trend toward less overanticoagulation 1 Kovacs M J et al. Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism. Ann Intern Med. 2003;138: Crowther MA et al. A Randomized Trial Comparing 5-mg and 10-mg Warfarin Loading Doses. Arch Intern Med. 1999;159: Holbrook. Evidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. doi: /chest Return to Things to Consider when Starting Patients on Warfarin Copyright 2014, MAQI 2 For questions or permissions, please Version 1.2, reviewed/updated on 2/1/15 Page 21
6 Factors Increasing or Decreasing Warfarin Sensitivity When determining the appropriate starting dose of warfarin and making dose adjustments, it is important to consider if the patient may have increased or decreased sensitivity to warfarin. Higher Sensitivity (Consider lower starting dose) Lower Sensitivity (Consider higher starting dose) Baseline INR >1.2 Baseline INR < 1.2 Advanced age (>65) Younger age (<55) 1 Female gender 2 Male gender 2 Low body weight (<110 pounds) >200 pounds 2 Asian ancestry 3 African American ancestry 2 Recent surgery and blood loss 2 Diet high in Vitamin K 2 Comorbidities: CHF, renal disease, liver disease, and cancer 4 Impaired nutritional status Alcohol abuse 4 Concurrent use of medications known to increase INR, including amiodarone, acetaminophen, and many antibiotics and antifungals Acute illness (diarrhea, fever) 4 1 Crowther MA et al. A Randomized Trial Comparing 5-mg and 10-mg Warfarin Loading Doses. Arch Intern Med. 1999;159: Absher. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother Oct;36(10): Dang. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother Jun;39(6): Epub 2005 Apr 26. doi: /aph.1E566 4 White. Patient factors that influence warfarin dose response. J Pharm Pract Jun;23(3): doi: / Epub 2010 May 6. doi: / Copyright 2014, MAQI 2 For questions or permissions, please Version 1.2, reviewed/updated on 2/1/15 Page 22
7 Warfarin Initiation Nomograms Warfarin Initiation Nomogram (5mg starting dose, target INR range 2-3) 1 This algorithm was developed for in-patients started on 5mg with an INR target range of 2-3 and monitored with daily INRs. It may not be applicable to outpatient use in which daily INRs are not practical. DAY 1 INR DAY 2 < > 2.5 DAY 3 < > 3.0 DAY 4 < > 3.0 DAY 5 < > 3.0 DAY 6 < > Crowther.Ann Int Med, 127:333, 1997 Dose 5 mg 5 mg 2.5 mg mg 0 mg 5-10 mg mg mg 0 mg 10 mg mg 0-5 mg 0 10 mg mg 0-5 mg mg 5-10 mg mg 0 Copyright 2014, MAQI 2 For questions or permissions, please Version 1.2, reviewed/updated on 2/1/15 Page 23
8 Warfarin Initiation Nomogram (10mg starting dose, INR target range 2-3) 2 This algorithm was developed and validated in acute VTE patients treated in the outpatient setting and receiving 10mg of warfarin for the first two days of treatment. Patients included in the study were deemed to not be high-risk for bleeds. 3 Use in other patient populations, such as atrial fibrillation, has not been validated. 2 Kovacs M J et al. Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism. Ann Intern Med. 2003;138: Patients excluded from study: baseline INR>1.4, platelet count <50 K/uL, age < 18 years, required hospitalizations, considered high-risk for major bleeding (including interacting medications) Copyright 2014, MAQI 2 For questions or permissions, please Version 1.2, reviewed/updated on 2/1/15 Page 24
9 Conversion from TSOACs to Warfarin (Coumadin ) Generic Instructions (Trade Name) Dabigatran (Pradaxa ) 1 Adjust the starting time of warfarin based on creatinine clearance as follows: o For CrCl 50 ml/min, start warfarin 3 days before discontinuing dabigatran. o For CrCl ml/min, start warfarin 2 days before discontinuing dabigatran. o For CrCl ml/min, start warfarin 1 day before discontinuing dabigatran. o For CrCl <15 ml/min, no recommendations can be made. Because dabigatran can increase INR, the INR will better reflect warfarin s effect only after dabigatran has been stopped for at least 2 days Apixaban (Eliquis ) 2 Apixaban affects INR, so INR measurements during co-administration with warfarin may not be useful for determining appropriate dose of warfarin. If continuous anticoagulation is necessary, discontinue apixaban and begin Warfarin (Coumadin ) with a concomitant parenteral anticoagulant when the next dose of apixaban would have been due, discontinuing the parenteral anticoagulant when INR reaches goal range. Rivaroxaban No clinical trial data are available to guide converting patients from rivaroxaban to (Xarelto ) 3 warfarin. Rivaroxaban affects INR, so INR measurements made during coadministration with warfarin may not be useful for determining the appropriate dose of warfarin. If continuous anticoagulation is necessary in A-fib, discontinue rivaroxaban and begin warfarin bridged with a concomitant parenteral anticoagulant when the next dose of rivaroxaban would have been due. Edoxaban For patients on 60 mg of edoxaban, reduce dose to 30 mg and begin warfarin (Savaysa ) 4 concomitantly. For patients on 30 mg of edoxaban, reduce dose to 15 mg and begin warfarin concomitantly. During transition, INR should be done at least weekly just prior to daily dose of edoxaban (to minimize influence on INR). Discontinue edoxaban once a stable INR 2.0 is achieved. 1 Pradaxa package insert (updated 12/2013): radaxa.pdf 2 Eliquis package insert (updated 1/2014): 3 Xarelto package insert (updated 1/2014): 4 Savaysa package insert: Copyright 2014, MAQI 2 For questions or permissions, please Version 1.2, reviewed/updated on 2/1/15 Page 25
10 Most Clinically Relevant Warfarin-Drug Interactions Potentiation of Drug Effect (Increased INR) Acetaminophen Allopurinol Amiodarone Amoxicillin Aspirin Azithromycin Bactrim(TMP-SMX) Cimetadine Ciprofloxacin Citalopram Clarithromycin Clopidogrel Cotrimoxazole Diltiazem Entacapone Erythromycin Fenofibrate Fish Oil Fluconazole Fluvastatin Gemcitabine Gemfibrozil Levofloxacin Lovastatin Metronidazole Miconazole (Suppository and Gel) Omeprazole Propafenone Propanolol Simvastatin SSRI s Tamoxifen Tetracycline Tramadol Inhibition of Drug Effect (Decreased INR) Barbiturates Bosentan Carbamazepine Cigarette Smoking Chlordiazepoxide Ginseng Griseofulvin Mercaptopurine Multivitamin Supplement Nafcillin Phenobarbital Ribavarin Rifampin Secobarbital St. John s wort Phenytoin For a more comprehensive list of potential drug, food, and dietary supplement interactions see Ageno et al. Antithrombotic Therapy and Prevention of Thrombosis, 9 th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Sources: Holbrook AM, et al. Systematic Overview of warfarin and its drug and food interactions. Arch Intern Med May 23;165(10): doi: /archinte Badyal DK, Dadhich AP. Cytochrome P450 and drug interactions. Ind J Pharmacol 2001;33: Stading JA, Faulkner MA, Skrabal MZ. Effect of tobacco on INR.[Letter]. Am J HealthSystem Pharm 2007;64:805. Return to Things to Consider when Starting Patients on Warfarin Copyright 2014, MAQI 2 For questions or permissions, please Version 1.2, reviewed/updated on 2/1/15 Page 26
11 Warfarin Patient Education Checklist Completed Topic What is anticoagulation and how does warfarin work? Why does patient need to start taking warfarin? How to take warfarin? (time of day, dose, weekly schedule, etc.) What is the expected duration of treatment? How is warfarin monitored? (INR testing, goal target range for patient, frequency of testing, etc.) What are the risks and side-effects of warfarin? What are the signs/symptoms of bleeding or clotting to watch for? What are the main factors influencing INR? (dietary intake of vitamin K, general health, activity level, alcohol, other medications/supplements, etc.) Ways to keep INR in range (consistent vitamin K content in diet, limit alcohol use, adhere to dosing instructions, etc.) What to do for missed doses? What are the drug-drug interactions to watch for? (including OTC and herbal supplements) What are the drug-food interactions to watch for?(vitamin K rich foods, alcohol, etc.) What are some other necessary lifestyle changes? (no contact sports, fall avoidance, pregnancy) When and how to notify clinic? s/sx of bleeding medication/supplement changes illness/changes in health status Clinic contact information When to seek immediate medical attention? Copyright 2014, MAQI 2 For questions or permissions, please Version 1.2, reviewed/updated on 2/1/15 Page 27
12 Topic General warfarin (Coumadin ) information Warfarin monitoring Diet Drug Interactions Reducing risk of complication Other patient resources Warfarin Education Material Links MAQI Toolkit Medication Guide Link Link Link Link Link Copyright 2014, MAQI 2 For questions or permissions, please Version 1.2, reviewed/updated on 2/1/15 Page 28
TSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
FDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
Anticoagulation Toolkit
Anticoagulation Toolkit A Consortium-Developed Quick Reference for Anticoagulation This toolkit was produced by the Michigan Anticoagulation Quality Improvement Initiative (MAQI 2 ), a consortium of anticoagulation
DVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg
Anticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
STROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
The Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
How to Manage Warfarin Management
How to Manage Warfarin Management Katie McClendon, PharmD, BCPS University of Mississippi School of Pharmacy AS MANDATED BY ACCME SPEAKERS ARE ASKED TO DISCLOSE ANY REAL OR APPARENT CONFLICT RELATED TO
STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
New Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS BRIAN CRYDER, PHARMD BCACP
A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS BRIAN CRYDER, PHARMD BCACP LEARNING OBJECTIVES AS A RESULT OF THIS PRESENTATION, THE AUDIENCE WILL BE ABLE TO 1. DISCUSS THE KEY DIFFERENCES BETWEEN
A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS
A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS BRIAN CRYDER, PHARMD BCACP LEARNING OBJECTIVES AS A RESULT OF THIS PRESENTATION, THE AUDIENCE WILL BE ABLE TO 1. DISCUSS THE KEY DIFFERENCES BETWEEN
Cardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
The author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
MEDICAL ASSISTANCE BULLETIN
ISSUE DATE June 22, 2015 SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical
Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2
Bleeding/Clotting Risk Evaluation Tools for Atrial Fibrillation Patients Before prescribing anticoagulants, providers should weigh the risk of thrombosis against the risk of bleeding. The tools below can
The speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered
2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
Optimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
New Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
Disclosure/Conflict of Interest
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
Venous Thromboembolic Treatment Guidelines
Venous Thromboembolic Treatment Guidelines About the NYU Venous Thromboembolic Center (VTEC) The center s mission is to deliver advanced screening, detection, care, and management services for patients
NOACS AND AF PEARLS AND PITFALLS DR LAURA YOUNG HAEMATOLOGIST
NOACS AND AF PEARLS AND PITFALLS DR LAURA YOUNG HAEMATOLOGIST NGAIRE IS 70 YEARS OLD AND IN AF. SHE HAS NO MURMURS, NORMAL BLOOD PRESSURE, EGFR OF 65ML/MIN AND NO SIGNIFICANT PAST MEDICAL HISTORY. REGARDING
Appendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
DOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
WARFARIN DOSING GUIDELINE
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
Dabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
9/28/15. Dabigatran. Rivaroxaban. Apixaban. Edoxaban. From the AC Forum Centers of Excellence website: Dabigatran, Rivaroxaban, & Apixaban
Identify the FDA approved direct oral anticoagulants (DOACs) Linda Kelly, PharmD, PhC, CACP Presbyterian Healthcare Services Distinguish the differences in the dosing of DOACs for various indications Describe
East Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
Traditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps
Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps Cheryl Ea, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
Management for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline MedStar Health
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians
CHADS score of 5 or 6 Recent (within 3mo) stroke or TIA Rheumatic valvular heart disease CHADs score of 3 or 4
LAMC Department of Pharmacy Services: ANTICOAGULATION: Surgical Intervention Table 1: Classification of Surgical interventions according to bleeding risk t required to discontinue anticoagulation Dental
3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
Time of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
DEEP VEIN THROMBOSIS: TREATMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
Dorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
Clinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
The New Kids on the Block: Oral Anticoagulants
The New Kids on the Block: Oral Anticoagulants Lauren E. Odum, PharmD, BCPS Clinical Assistant Professor UMKC School of Pharmacy at MU April 11, 2014 Objectives Be able to Understand the major trials leading
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis )
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) The contents of this CPG are to be used as a guide. Healthcare professionals
Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
Anticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
PROTOCOL TITLE: Ambulatory Initiation and Management of Warfarin for Adults
PROTOCOL NUMBER: 7 PROTOCOL TITLE: Ambulatory Initiation and Management of Warfarin for Adults THIS PROTOCOL APPLIES TO: UW Health Clinics: all adult outpatients with an active order for warfarin TARGET
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose Warfarin vs the NOACs Dr. Lori McIntosh D.O. Board Certified Neurologist Objectives Be able to list the current options of
Comparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC
To Bridge or Not to Bridge Periop Anticoagulation Management Don Weinshenker, MD Ambulatory Care Denver VAMC Financial Disclosure Information Nothing to report Periop AC Management Chronically anti-coagulated
Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
NOVEL ORAL ANTICOAGULANT THERAPY An audit from 6 Acute Hospitals
NOVEL ORAL ANTICOAGULANT THERAPY An audit from 6 Acute Hospitals Co-Investigators: Bernard Carr, Dr Aisling O Leary, Dr Michael Barry Pharmacy Interns: Karyn Clerkin, Aoife Boyle, Kieran Walsh, Mairead
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
What You Should NOAC About the New Anticoagulants. Dr Calum Young Cardiologist
What You Should NOAC About the New Anticoagulants Dr Calum Young Cardiologist Overview The Burden of AF What s Wrong With Warfarin? The Era of NOACs NOACs in New Zealand Clinical Trials with NOACs Potential
Anticoagulants for venous thromboembolic disease- Optimizing the old, ushering in the new.
Anticoagulants for venous thromboembolic disease- Optimizing the old, ushering in the new. Daniel A. Forman, DO RPS Hematology Oncology daniel.forman@readinghealth.org 610 509 5067 cell RHS Anticoagulation
New Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
Coumadin Assisted Dosing - InPatients
MANUAL: PHARMACY POLICY AND PROCEDURE Page 1 of 6 SECTION: INCLUDES: MEDICATION USE, PRESCRIBING AND ORDERING Coumadin Assisted Dosing - InPatients Purpose: To provide guidelines to inpatient pharmacists
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
DABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
Updates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
Thrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
Which Drugs to Use? Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Which Drugs to Use? Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE: Support provided
Objectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
Introduction. Background to this event. Raising awareness 09/11/2015
Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness
Antiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN,
PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals, including primary care physicians,
Rivaroxaban (Xarelto ) by
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
Anticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More information for patients and caregivers can be accessed at http://www.xarelto-us.com/.
Janssen Research & Development Submits Application to U.S. FDA for XARELTO (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome RARITAN, DECEMBER 29, 2011 -
New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
08/03/2015. Anticoagulation in the Elderly: Using New Direct Acting Oral Anticoagulants (DOACs) Indications for Anticoagulation
Anticoagulation in the Elderly: Using New Direct Acting Oral Anticoagulants (DOACs) Steven Zweig, MD, MSPH MU School of Medicine MU Interdisciplinary Center on Aging Caring for the Frail Elderly Conference
Updates to the Alberta Drug Benefit List. Effective January 1, 2016
Updates to the Alberta Drug Benefit List Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
Advanced Issues in Peri-Operative VTE Prevention
Advanced Issues in Peri-Operative VTE Prevention Michael-Anthony (M-A) Williams, M.D. Consultant Physician Centura Medical Consultants September 27th, 2012 Main Topics 1. The perils of the early mover-
2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS,
Dabigatran revisited
Dabigatran revisited 22 Dabigatran has been available for general practitioners to prescribe since July, 2011. Twelve months later, over 14 000 patients were being dispensed this medicine. Dabigatran is
1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
Breadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
Committee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent Primary Care Center
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent